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Abstract 
Aims/hypothesis  We analysed the association between humoral autoreactivity to zinc 
transporter-8 (ZnT8) and the SLC30A8 rs13266634 polymorphism (Arg325Trp), which is 
located at the most distal loop in the ZnT8 protein. 
Methods  Autoantibodies to ZnT8 were determined by RIA in 270 patients with type 1 
diabetes using ZnT8 carboxy-terminal constructs (amino acids 268–369) carrying 
325Trp(CW) and 325Arg(CR) and a hybrid construct (CW-CR). Forty-four ZnT8 
autoantibody-positive sera with genomic DNA were used to examine the association between 
reactivity to ZnT8 constructs and the rs13266634 genotype. 
Results  Seventy-five patients reacted to the CW-CR hybrid construct, whereas 37 and 36 
patients reacted to the CW and CR constructs, respectively. All sera positive for either CW or 
CR autoantibodies were positive for CW-CR autoantibodies. Among 19 patients with a 
325Arg(CC) genotype, 5% had CW-specific autoantibodies, 42% had CR-specific 
autoantibodies and 32% had dual reactivity. Conversely, 73% of 15 patients with the 
325Trp(TT) genotype had CW-specific autoantibodies, no patients had CR-specific 
autoantibodies and 13% had dual reactivity. Nine of the ten patients (90%) with the CT 
genotype reacted with either CR or CW constructs. The titre of CR autoantibodies in patients 
carrying the C allele was significantly higher than that in TT homozygotes (p<0.0001). In 
contrast, the titre of CW autoantibodies in patients carrying a T allele was significantly higher 
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than that in CC homozygotes (p<0.005). No evidence of an association between rs13266634 
and type 1 diabetes was observed. 
Conclusions/interpretation  These results indicate that variant residue at amino acid 325 is a 
key determinant of humoral autoreactivity to ZnT8 and the SLC30A8 genotype is an 
important determinant of autoantibody specificity. 
 




aa amino acids 
CR zinc transporter-8 carboxy-terminal construct carrying 325Arg 
CW zinc transporter-8 carboxy-terminal construct carrying 325Trp 
CW-CR hybrid ZnT8 construct generated by fusion of CW and CR 
SNP single nucleotide polymorphism 
ZNT8 zinc transporter-8 
ZnT8A zinc transporter-8 autoantibodies 
 
Introduction 
Zinc transporters  belonging to the SLC30 protein family are multipass transmembrane 
proteins with a role in the transport of zinc out of the cytoplasm or into vesicles [1]. One of 
these, zinc transporter-8 (ZnT8), is specifically produced in the pancreatic beta cells and 
localised into insulin secretory granules and was recently identified as a major autoantigen in 
human type 1 diabetes [2, 3]. The gene coding for ZnT8 (solute carrier family 30 member 8; 
SLC30A8) is mapped to chromosome 8q24.11 [3]. The reference gene contains eight exons, 
spans 37 kb, and encodes a 369 amino acid protein. In genome-wide association studies 
Sladek and colleagues reported an association between a non-synonymous variant in 
SLC30A8 (rs13266634; Arg325Trp) and susceptibility to type 2 diabetes [4]. The fact that 
major epitope(s) for ZnT8 autoantibodies (ZnT8A) lie within the cytoplasmic domain of the 
molecule (amino acids [aa] 268–369) [2] and the variant residue at aa325 is located at the 
most distal extension of the molecule into the cytoplasm [5] prompted us to analyse the 
association between humoral autoreactivity to ZnT8 and the SLC30A8 polymorphism. 
 
Methods 
Initially, sera from 270 Japanese patients with type 1 diabetes (61% female), including 112 
new-onset patients, were used to identify the ZnT8A-positive samples. The median age at 
onset and median duration of diabetes were 25.0 (range 1.0–77.0) years and 2.0 (range 
0.0–42.0) years, respectively. Among these patients, genomic DNA samples were available 
for 171 patients and were genotyped for the rs13266634 single nucleotide polymorphism 
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(SNP). To examine the relationship between humoral autoreactivity to ZnT8 and the SLC30A8 
variant, ZnT8A-positive patients with available genomic DNA samples were used. All 
patients met the criteria of the revised American Diabetes Association for type 1 diabetes [6].  
Furthermore, 114 genomic DNA samples from healthy control participants were also 
genotyped for the rs13266634 SNP to examine the contribution of this SNP to susceptibility 
to type 1 diabetes in the Japanese population. This study was approved by the appropriate 
ethical committees and informed consent was obtained from all participants. 
 The ZnT8 complementary DNA (cDNA) constructs used in this study were the 
cytoplasmic carboxy-terminal domains (aa268–369) of human ZnT8 carrying either 
325Trp(CW) or 325Arg(CR) and a fusion of the CW and CR with a 
CLFCEDPCDPSTPPGSSGGGKDFSILLME hinge junction generated by PCR. These cDNA 
were cloned into a pCDNA3.1 directional TOPO vector (Invitrogen, Carlsbad, CA, USA).  
The hybrid ZnT8 construct was designated as CW-CR. 
 Autoreactivity to ZnT8 CW, CR and CW-CR constructs was determined by 
radiobinding assay as described previously [2]. Positive control and negative control sera 
were included in each assay, and the antibody titres were expressed as an index defined as 
follows: (cpm in the unknown sample–cpm in the negative control)/(cpm in the positive 
control–cpm in the negative control). As a positive control for all constructs, a New Zealand 
white rabbit antiserum raised against an affinity-purified glutathione S-transferase fusion 
protein containing the cytoplasmic domain (aa268–369) of human ZnT8 was used.  
Classification of a sample as positive for ZnT8A was based on the 99th percentile of sera 
from 139 healthy control participants with no family history of diabetes. This corresponded to 
an index of 0.018 for CW autoantibodies, 0.016 for CR autoantibodies and 0.007 for CW-CR 
autoantibodies, respectively. The inter- and intra-assay CV were 5.9% and 6.8% for CW 
autoantibodies, 10.4% and 5.7% for CR autoantibodies and 9.6% and 4.6% for CW-CR 
autoantibodies, respectively.   
 The SLC30A8 rs13266634 C > T polymorphism was genotyped by PCR-RFLP. The 
PCR products were digested with a PvuII, resolved on a 3% agarose gel and stained with 
ethidium bromide. No deviations from Hardy–Weinberg equilibrium were observed in control 
participants (p=0.36). Statistical analyses were performed with the StatView 5.0 software 
(SAS Institute, Cary, NC, USA). The correlation between autoantibody titres was analysed 
using Spearman’s rank-correlation test. Group comparisons of ZnT8A prevalence and titre 
were analysed by 2 test and Mann–Whitney U test, respectively. A value of p<0.05 was 
considered statistically significant. 
 
Results 
Of 270 patients with type 1 diabetes, 75 (28%) were ranked as positive for ZnT8 CW-CR 
autoantibodies, whereas the responses to autoantibodies to CW and CR constructs were 
positive in 37 (14%) and 36 (13%) patients, respectively. All sera positive for either CW or 
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CR autoantibodies were positive for CW-CR autoantibodies. However, 20 (7%) patients were 
CW-CR autoantibody-positive but negative for autoantibodies to CW and CR. The prevalence 
of CW-CR, CW and CR autoantibodies in 112 new-onset patients was 36%, 16% and 20%, 
respectively. CW-CR autoantibodies were more prevalent in younger (≤20 years) new-onset 
patients compared with patients with age at onset of >20 years (47% vs 28%, p<0.05).  
Among 171 patients with genomic DNA, 63 patients (37%) were 325Arg (CC) homozygotes 
in SLC30A8, 36 (21%) were homozygotes for the 325Trp (TT) and 72 (42%) were CT 
heterozygotes. The allele frequency of rs13266634 in patients was not significantly different 
from that in the 114 healthy control participants (C allele: 57% and T allele: 43%, OR: 1.02, 
95%CI: 0.73–1.43). 
 Forty-four patients were positive for CW-CR autoantibodies among the 171 patients 
with genomic DNA samples and they were used to examine the association between humoral 
autoreactivity to ZnT8 and the SLC30A8 variant. Among 19 patients with the CC genotype 
eight patients (42%) reacted with the CR construct alone, six patients (32%) reacted with both 
CR and CW constructs, and only one patient (5%) reacted with the CW construct alone.  
Conversely, 11 (73%) of 15 patients with the TT genotype reacted with the CW construct 
alone and no one reacted with the CR construct. Nine of the ten patients (90%) with the CT 
genotype reacted with either the CR or the CW construct. The prevalence of CR 
autoantibodies in patients carrying a C allele (CC+CT) was therefore significantly higher than 
that in TT homozygotes (p<0.0001). In contrast, autoantibodies to the CW construct were 
more prevalent in patients with a T allele (TT+CT) than in those with the CC genotype 
(p<0.01) (Table 1). As shown in Fig. 1a, there was no overall correlation between titres of CW 
autoantibodies and CR autoantibodies (R=0.069, p=0.66) and the autoreactivity to ZnT8 
variant forms was closely associated with the SLC30A8 genotype. The titre of CR 
autoantibodies in patients with a C allele was significantly higher than that in TT 
homozygotes (0.139±0.158 vs 0.002±0.014, P<0.0001) (Fig. 1b). In contrast, the titre of CW 
autoantibodies was significantly higher in patients with a T allele than in CC homozygotes 
(0.093±0.103 vs 0.029±0.053, p=0.0024) (Fig. 1c). 
 
Discussion 
This study has demonstrated that (1) the SLC30A8 variant residue at aa325 is critically 
involved in the binding of ZnT8A; (2) the SLC30A8 genotype is an important determinant of 
autoantibody specificity; (3) the hybrid CW-CR construct is a superior probe for the detection 
of ZnT8A; and (4) rs13266634 may not contribute to the genetic susceptibility to type 1 
diabetes in the Japanese population. The first two points were recently proven in American 
patients [7]. However, the prevalence of CW-specific autoantibodies in patients with either 
CW or CR autoantibodies was higher in this study (35% vs 13%, p<0.0005) because of the 
difference in the frequency of TT homozygotes between Japanese and American. Currently, it 
is not known whether Arg325Trp SNP affects the functional properties of ZnT8. However, the 
5 
 
amino acid chain that includes 325Arg has a protein kinase A and protein kinase C recognition 
motif (R-X-S/T) and rs13266634 SNP disrupts this motif, indicating the possible alteration of 
zinc transporter function. As differences in the epitope specificity of autoantibodies to GAD65 
and insulinoma-associated antigen-2 are linked to the progression or the clinical heterogeneity 
of type 1 diabetes in Japanese patients [8, 9], it is worth investigating the clinical role of ZnT8 
CW and CR autoantibodies in the Japanese population. 
 Although the molecular mechanisms for the production of anti-islet autoantibodies in 
type 1 diabetes are largely unknown, the interactions of autoantibody with protein antigen 
usually depend on the conformational structure of the epitopes [10]. Tryptophan (W) encoded 
by TGG is a hydrophobic amino acid that tends to cluster on the inside of the protein to avoid 
contact with the aqueous environment and so it is unlikely to form the same bonding 
arrangement as the hydrophilic amino acid, arginine (R) encoded by CGG. This may explain 
the observed differences in binding where the majority of ZnT8A in patients carrying the TT 
genotype did not recognise the CR construct. However, the findings that 37% of CC 
homozygous patients reacted with the CW construct and 13% of TT homozygous patients 
reacted with the CR construct indicate that the amino acids neighbouring aa325 are also 
involved in the ZnT8A binding. 
 The strength of this study is its use of a hybrid ZnT8 molecule (CW-CR) to identify 
ZnT8A-positive individuals; this allowed a 15–20% increase of sensitivity with the same 
specificity in our patients. Limitations are that about 60% of samples were obtained from 
long-standing cases and a minimum OR to obtain sufficient power (>80%) under the 
assumption of =0.05 and observed allele frequency among controls was 1.9 in our 
case-control study. 
 In conclusion, the present study confirmed that a variant residue at aa325 is a key 
determinant of humoral autoreactivity to ZnT8 and that the SLC30A8 genotype is an 
important determinant of autoantibody specificity. Furthermore, the utility of the hybrid ZnT8 
construct should be considered for ZnT8A screening in the relatives of patients with type 1 
diabetes and in the general population. 
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Table 1  The prevalence of autoantibodies to the ZnT8 CR or CW construct in ZnT8 





Prevalence of autoantibodies to: 
CR CW 
CC  19 14 (73.7) 7 (36.8)
a 
CT  10 9 (90.0) 6 (60.0) 
TT  15 2 (13.3) 
b 13 (86.7) 
Data are n (%) 
ap<0.01 vs CT+TT genotype; bp<0.0001 vs CC+CT genotype 
 
Fig. 1  Correlation between the reactivity to ZnT8 CR and CW construct (a) and the 
comparison between the titres of ZnT8 autoantibodies and SLC30A8 genotype (b, c) in 
Japanese patients with type 1 diabetes. (a) White circles, CC genotype; black circles, CT 
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